Evolus (EOLS)
(Delayed Data from NSDQ)
$12.91 USD
-0.02 (-0.15%)
Updated Aug 7, 2024 03:59 PM ET
After-Market: $12.92 +0.01 (0.08%) 7:22 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
EOLS 12.91 -0.02(-0.15%)
Will EOLS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EOLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EOLS
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
EOLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Green Thumb Industries Inc. (GTBIF) Surges 22.3%: Is This an Indication of Further Gains?
Other News for EOLS
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Evolus (EOLS) and Humana (HUM)
Evolus Continues To Make Progress
Evolus Poised for Continued Growth with Strong Market Performance and Expanding Customer Base: Maintains Buy Rating
Evolus (EOLS) Receives a Buy from Stifel Nicolaus
Evolus Rides High on Jeuveau Sales Surge and Financial Milestones: A Bullish Buy Rating